Visgenx

Developer of gene therapy for age related muscular degeneration

placeSan Diego, California, United States calendar_todayFounded 2018 groups9 employees language visgenx.com

Innovation

3 patent families (1 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 33 times.

YearFilings
20221
20232
20241
20252

Investor mix

5 investors on record.

Investor typeCountShare
Venture capital360%
Accelerator & incubator120%
Other / undisclosed120%
Coming soon